Evidence map›Paper›PMID 40699499›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025

Mental health burden in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis: Depression and anxiety.

Jovan Javorac, Dejan Živanović, Miljana Miladinović, Andrijana Mikić, Vesna Dukanac, Miroslav Ilić, Ana Milenković, Sonja Peričević Medić, Tamara Popović, Svetlana Kašiković Lečić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jovan JavoracDepartment of Internal Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Dejan ŽivanovićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Department of Psychology, Academy of Human Development, Belgrade, Serbia.
Miljana MiladinovićFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Andrijana MikićDepartment of Psychology, Academy of Human Development, Belgrade, Serbia.
Vesna DukanacDepartment of Psychology, Academy of Human Development, Belgrade, Serbia.
Miroslav IlićDepartment of Internal Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Ana MilenkovićDepartment of Internal Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Sonja Peričević MedićDepartment of Occupational Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Department of Occupational Medicine, Institute of Occupational Health of Novi Sad, Novi Sad, Serbia.
Tamara PopovićClinic for Psychiatry, University Clinical Center of Vojvodina, Novi Sad, Serbia.
Svetlana Kašiković LečićDepartment of Internal Medicine, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimProgressive pulmonary fibrosis (PPF) is an umbrella term for several interstitial lung diseases characterized by the progressive proliferation of fibrous tissue within the lung interstitium. This study aimed to assess the prevalence of depressive and anxiety symptoms among PPF patients and their repercussions on quality of life.

methodsThirty-seven PPF patients undergoing treatment at the Institute for Pulmonary Diseases of Vojvodina, Serbia were enrolled. The SGRQ questionnaire assessed quality of life, while the DASS-21 questionnaire evaluated anxiety and depression symptoms. Sociodemographic and clinical factors were correlated with questionnaires outcomes, and the influence of anxiety and depression symptoms on quality of life was examined.

resultsAnxiety symptoms were detected in 56.75% of PPF patients and were more prevalent in patients previously diagnosed with depression and/or anxiety. Depression symptoms were detected in 45.95% of PPF patients and were more pronounced in the patients with longer duration of PPF, and positive history of malignancies. Stress symptoms were linked to lower PaO2 values and were detected in 37.84% of participants. HRQL was moderately to severely decreased and was lower in patients who, in addition to PPF, also suffered from other respiratory diseases, and was statistically significantly associated with lower DLCO values. A statistically significant correlation has been proven between the presence of anxiety, depression, and stress symptoms and HRQL, as measured through the "Symptoms" and "Impact" subscales of the SGRQ questionnaire.

conclusionsAnxiety and depression symptoms are highly prevalent among PPF patients, exerting substantial impacts on their quality of life.

Identifiers

PMID40699499
PMCPMC12242862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.